Effects of probiotics on lipid profile, glycemic index, oxidative stress and inflammatory markers in patients with diabetes type 2

Effects of probiotics on lipid profile, glycemic index, oxidative stress and inflammatory markers in patients with diabetes type 2; a clinical trial study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016071127879N2

Enrollment

Registered

2016-09-22

Start date

2016-08-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Intervention: patients in the treatment group received 1500 mg probiotic capsules twice daily (after lunch and dinner meals) for 6 weeks. The lactobacillus Probiotics contain: L. acido

Treatment - Drugs

Placebo

Intervention: patients in the treatment group received 1500 mg probiotic capsules twice daily (after lunch and dinner meals) for 6 weeks. The lactobacillus Probiotics contain: L. acidophilus 3.6 billi

Control: Placebo Group receiving 1500 mg Magnesium Stearate capsules twice daily, for six weeks.

Eligibility

Sex/Gender

All

Age

25 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Patients with diabetes type 2 are enrolled with FBS=126 mgr/dl; less than 15 years of medical history; the age range is 25 to 65 years; the elective subjects, next drugs prescribed by physicians, should be controlled the status of glucose and lipid levels and during the study could use these drugs without changing in the prior dosage. Exclusion Criteria: Patients with diabetes type 2 that used alternative treatments like hormone therapy or supplemental vitamins; also those used tobacco and alcohol; patients with chronic kidney disease; liver, lung, chronic or acute inflammatory disease (especially acute pancreatic inflammation and Endocarditis); heart valve disease; short bowel syndrome; allergies; people with low immune system ability (autoimmune); pregnant or lactating women.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Lipid Profile (Tg,Total Chol, LDL-C, HDL-C). Timepoint: Before and After Intervention. Method of measurement: Autoanalyzer.;Serum Glucose. Timepoint: Before and after Intervention. Method of measurement: Autoanalyzer.;Serum Insulin Levels. Timepoint: Before and After Intervention. Method of measurement: ELISA.;Hs-CRP. Timepoint: Before and after intervention. Method of measurement: ELISA.;IL-6. Timepoint: Before and After Intervention. Method of measurement: Autoanalyzer.;Malodialdehyde (MDA). Timepoint: Before and after Intervention. Method of measurement: Specterophotometery.	—

Measure

Time frame

Lipid Profile (Tg,Total Chol, LDL-C, HDL-C). Timepoint: Before and After Intervention. Method of measurement: Autoanalyzer.;Serum Glucose. Timepoint: Before and after Intervention. Method of measurement: Autoanalyzer.;Serum Insulin Levels. Timepoint: Before and After Intervention. Method of measurement: ELISA.;Hs-CRP. Timepoint: Before and after intervention. Method of measurement: ELISA.;IL-6. Timepoint: Before and After Intervention. Method of measurement: Autoanalyzer.;Malodialdehyde (MDA). Timepoint: Before and after Intervention. Method of measurement: Specterophotometery.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAbbas Yousefinejad

Bushehr University of Medical Sciences

yousefinejad.abs@gmail.com+98 77 3345 0134

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026